YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The fair value estimate for Pulse Biosciences has shifted from US$45.25 to US$54.00 per share, which is about a 19% move in the underlying price target framework. Analysts link this change to fresh enthusiasm around the company's nsPFA tec…
Investor pulses were racing for Pulse Biosciences (NASDAQ: PLSE) on Wednesday, as it was one of the better-performing medical device stocks on the market. This came down to an initiation of coverage by an analyst, backed by a rather positi…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As the month of August 2026 comes to a close, the broader stock market has exhibited a mix of late-summer consolidati…
Fearless Girl looking up at Wall Street at Night by Tim Pruss via iStock The S&P 500 Index ($SPX) (SPY) closed down by -0.52% on Monday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down by -0.51%, and the Nasdaq 100 Index ($IUXX)…
Inside NYSE by Orhan Akkurt via Shutterstock The S&P 500 Index ($SPX) (SPY) is down by -0.15% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down by -0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.28%. E-mini S&P futur…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Philip TaylorCo-Chair of the Board and Chief Executive Officer - Paul LaVioletteChief Financial Officer - Jon SkinnerCo-Chair…
(RTTNews) - The following biotech stocks reached a 52-week high on August 3, 2026, driven by key catalysts such as upcoming quarterly reports or the initiation of clinical trials. AngioDynamics Inc. (ANGO) AngioDynamics, a medical technolo…
(RTTNews) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results. Incyte Corporation (INCY) Incyte is a biopharmaceutical company primarily engaged in discoverin…
Key Points CEO Paul LaViolette acquired 15,000 shares for a total cost of ~$295,000 on May 11, 2026. This transaction increased direct holdings by ~1,773.05%, raising the total to 15,846 shares post-trade. The purchase was effected entirel…
On May 11, 2026, Paul A. LaViolette, Chief Executive Officer of Pulse Biosciences(NASDAQ:PLSE), a developer of non-thermal bioelectric treatments, reported the direct purchase of 15,000 shares of common stock in an open-market transaction,…
Pulse Biosciences, Inc. (NASDAQ:PLSE) is one of the must-buy small cap stocks to buy. On April 7, Pulse Biosciences, Inc. (NASDAQ:PLSE) announced that it had enrolled the first patients in NANOPULSE-AF. This is the company’s US clinical tr…
Pulse Biosciences PLSE recently announced the enrollment of the first patients in its NANOPULSE-AF investigational device exemption (IDE) pivotal study, marking a significant milestone in the company’s clinical development pipeline. The st…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Liane Teplitsky New title: Chief operating officer, Pulse Biosciences Previous title: CEO,…
(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, Thursday, announced the appointment of Liane Teplitsky as Chief Operating Officer. Further, the company said that it has expanded the role of David Kenigsberg as f…
(RTTNews) - Pulse Biosciences Inc. (PLSE) has taken a major step forward in its atrial fibrillation program, enrolling the first patients in its pivotal U.S. Investigational Device Exemption (IDE) study, NANOPULSE-AF. The milestone follows…
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif., April 07, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using pr…
Pulse Biosciences PLSE recently announced a strategic shift aimed at accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System. The initiative follows highly breakthrough clinical results from…
PARIS, March 18, 2026--(BUSINESS WIRE)--Truffle Capital, a leading European venture capital firm whose mission is to support the creation and growth of companies capable of becoming global leaders, unveils the Truffle MedTech 10 index. Thi…
[An arrow pointing downwards on top of a pile of US dollar bills.] * Pulse Biosciences (PLSE [https://seekingalpha.com/symbol/PLSE]) traded lower on Friday despite beating Street forecasts with its Q4 2025 financials after the healthcare e…
* Pulse Biosciences press release [https://seekingalpha.com/pr/20388541-pulse-biosciences-schedules-fourth-quarter-and-full-year-2025-financial-results-conference] (PLSE [https://seekingalpha.com/symbol/PLSE]): Q4 GAAP EPS of -$0.26 beats…
Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac Catheter System using Nanosecond Pulsed Field Ablation energy. Presented at the 31st Annual AF Symposium 2026 in B…
Health care stocks rose Friday afternoon, with the NYSE Health Care Index increasing 1.3% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission HAYWARD, Calif., February 03, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leve…
HAYWARD, Calif., December 29, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today…
Pulse Biosciences PLSE recently announced that the FDA has granted Investigational Device Exemption (“IDE”) approval to initiate its nPulse Cardiac Catheter Ablation System study for the treatment of paroxysmal atrial fibrillation. The app…
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Re…
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.16 per share a year ago. These figures are adjusted for non-recurring ite…
Pulse Biosciences PLSE recently reported encouraging late-breaking data from the first-in-human feasibility study of its nPulse Cardiac Surgical System. The study data were unveiled at the 39th European Association for Cardio-Thoracic Surg…
Pulse Biosciences PLSE recently reached a key milestone with the FDA’s approval of its Investigational Device Exemption (IDE) to initiate the NANOCLAMP AF study, evaluating its Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery Syste…
Pulse Biosciences PLSE recently reached a key milestone with the FDA’s approval of its Investigational Device Exemption (IDE) to initiate the NANOCLAMP AF study, evaluating its Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Surgery Syste…
Pulse Biosciences PLSE has announced the publication of its first-in-human clinical feasibility study in the Journal Thyroid, highlighting the effectiveness of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for treatin…
HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.11 billion market cap medical technology company with strong liquidity metrics, announced that a first-in-human clinical feasibility study has demonstrated the effectiveness of…
In trading on Thursday, shares of Pulse Biosciences Inc (Symbol: PLSE) crossed above their 200 day moving average of $17.34, changing hands as high as $17.88 per share. Pulse Biosciences Inc shares are currently trading up about 4.9% on th…
Key Points Total GAAP costs and expenses, including research and development as well as general and administrative expenses, increased 73.5% year over year for the three months ended June 30, 2025. Cash and cash equivalents climbed to $106…
Earnings Call Insights: Pulse Biosciences (PLSE) Q2 2025 MANAGEMENT VIEW * Paul Arthur LaViolette, President and CEO, described the ongoing expansion across three market development programs, emphasizing the clinical and commercial progres…